Conduit Pharmaceuticals I... (CDT)
NASDAQ: CDT
· Real-Time Price · USD
1.62
-0.05 (-2.99%)
At close: Aug 15, 2025, 3:59 PM
1.70
4.94%
After-hours: Aug 15, 2025, 06:40 PM EDT
Company Description
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility.
It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility.
The company was founded in 2019 and is based in San Diego, California.
Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Mar 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Andrew Regan |
Contact Details
Address: 4995 Murphy Canyon Road San Diego, California United States | |
| Website | https://www.conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000913142 |
| CUSIP Number | 20678X106 |
| ISIN Number | US20678X1063 |
| Employer ID | 36-3601505 |
| SIC Code | 3357 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Regan | Founder, Chief Executive Officer & Director |
| James Bligh | Interim Chief Financial Officer & Director |
| Dr. David Joszef Tapolczay | Head of Strategy & Licensing |
| Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | 10-Q/A | [Amend] Quarterly Report |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 424B3 | Filing |
| Aug 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 11, 2025 | S-8 | Filing |
| Aug 08, 2025 | 8-K | Current Report |
| Aug 06, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 31, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jul 31, 2025 | S-3 | Filing |